Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QuidelOrtho Corporation filings document an in vitro diagnostics company with Nasdaq-listed common stock under QDEL. Form 8-K disclosures cover quarterly and annual operating results, preliminary revenue estimates, financial guidance, Regulation FD communications and business commentary tied to point-of-care, labs, respiratory, cardiac and immunohematology diagnostics.
The company’s proxy and governance filings address annual meeting matters, board composition, executive compensation and shareholder voting information. Other current reports record leadership transitions, director changes, registered securities information and exhibit-based disclosures furnished with earnings releases and stockholder communications.
QuidelOrtho Corp director Joseph D. Wilkins Jr. reported equity compensation activity involving 6,829 shares. He received 6,829 shares of common stock on May 29, 2026 through the release of previously granted restricted stock units, with no sales reported. Following these transactions, he directly owns 18,705 shares of QuidelOrtho common stock. The filing also shows the corresponding exercise of 6,829 restricted stock units into common shares, with no remaining units from this grant after vesting.
QuidelOrtho Corp director Ann D. Rhoads reported equity compensation activity involving restricted stock units. She received 6,829 shares of Common Stock at no cost, related to previously reported restricted stock units. These restricted stock units, each representing one share of common stock, vested on May 29, 2026 and were exercised into common shares the same day. Following these transactions, she holds 23,257 shares of QuidelOrtho common stock directly, with no remaining position in the exercised restricted stock units.
QuidelOrtho Corp director Michael Edward L. received 6,829 shares of Common Stock as a stock award on May 29, 2026, when previously granted restricted stock units vested. These RSUs were exercised into Common Stock, bringing his direct holdings to 28,181 shares, with no open-market buying or selling.
QuidelOrtho Corp director Evelyn S. Dilsaver reported an equity award and related vesting of restricted stock units. On May 29, 2026, she acquired 6,829 shares of common stock at no cost through the release of previously reported restricted stock units. Each unit converted into one share of common stock when the units vested on May 29, 2026. Following these transactions, she directly holds 17,453 shares of QuidelOrtho common stock, and the reported restricted stock unit grant has been fully exercised.
QuidelOrtho Corp director Ann D. Rhoads reported routine equity compensation activity. She received a total of 1,407 shares of common stock on May 22, 2026 through the release of previously reported restricted stock units.
Footnotes state these restricted stock units each convert into one share of common stock and that their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors, occurring according to her elected deferral schedule. The filing shows no open‑market purchases or sales, only grants and conversions of equity awards.
QuidelOrtho Corp President and CEO Brian J. Blaser reported routine equity compensation activity. On May 15, 20,759 restricted stock units converted into an equal number of common shares, reflecting a scheduled vesting.
To cover tax obligations from this vesting, 10,252 common shares were withheld at $10.32 per share, a tax-withholding disposition rather than an open-market sale. Following these transactions, he holds 45,901 common shares directly and 40,073 common shares indirectly through a trust. Footnotes note that 20,759 shares vested on each of May 15, 2025 and May 15, 2026, with another 20,759 scheduled to vest on May 15, 2027.
FMR LLC amends a Schedule 13G to report beneficial ownership of 7,852,321.81 shares of Common Stock of QUIDELORTHO CORP, representing 11.5% of the class.
The filing states FMR LLC has sole dispositive power over 7,852,321.81 shares and sole voting power of 7,850,418.00 shares. Abigail P. Johnson is listed with sole dispositive power of 7,852,321.81 shares. Signatures indicate authority under a Power of Attorney effective April 13, 2026, with the amendment dated April 30, 2026.
QuidelOrtho Corp ownership update: Invesco Ltd. reported beneficial ownership of 3,117,469 shares of QuidelOrtho Common Stock, representing 4.6% of the class as of 03/31/2026. The filing states these shares are held of record by clients of Invesco Ltd., and Invesco reports sole voting power over 3,097,919 shares and sole dispositive power over 3,117,469 shares. The schedule is an amendment filed by the parent holding company and lists Invesco Advisers, Inc. and Invesco Capital Management LLC as relevant subsidiaries.
QuidelOrtho Corporation beneficial ownership disclosure: Newtyn Management, LLC reports beneficial ownership of 5,300,000 shares of common stock, representing 7.8% of the class as of April 29, 2026. The filing states this total reflects holdings of Newtyn TE Partners, LP (3,418,500 shares) and Newtyn Partners, LP (1,881,500 shares), with the aggregate percentage calculated from approximately 68,081,767 shares outstanding as of February 11, 2026.
QuidelOrtho Corporation ownership disclosure: Newtyn Management, LLC reports beneficial ownership of 4,558,472 shares of QuidelOrtho common stock, representing 6.7% of the class. The filing states this aggregate position combines holdings of Newtyn TE Partners, LP (2,921,980 shares) and Newtyn Partners, LP (1,636,492 shares) as of March 31, 2026. The 6.7% figure is calculated using 68,081,767 shares outstanding as of February 11, 2026, per the issuer's 10-K.